循环肿瘤DNA在转移性黑色素瘤靶向治疗及免疫治疗中的应用

被引：0

作者：

杜明丽

李桂香

吴文娟

赵磊

机构：

[1] 兰州大学第二医院肿瘤中心伽马刀治疗科

来源：

国际肿瘤学杂志 | 2020年 / 47卷 / 06期

关键词：

黑色素瘤; 分子靶向治疗; 循环肿瘤DNA; 免疫治疗;

D O I：

暂无

中图分类号：

R739.5 [皮肤肿瘤];

学科分类号：

100214 ;

摘要：

靶向治疗及免疫治疗是转移性黑色素瘤治疗的重要手段, 但治疗过程中监测患者疾病进展和治疗反应是精准治疗及个体化治疗的关键。循环肿瘤DNA作为一种无创性的"液态活检"手段, 因其对基因突变的高度敏感性、特异性, 以及可以被定性、定量和追踪等优势, 在监测转移性黑色素瘤靶向治疗及免疫治疗过程中的疾病进展、疗效评估、预后预测等方面显示出良好的应用价值。

引用

页码：381 / 384

页数：4

共 8 条

[1] 转移性恶性黑色素瘤分子靶向及免疫治疗进展 [J].

甄振华 ;

申传厚 .

中国肿瘤, 2014, 23 (10) :854-859

[2] Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy [J].

Haselmann, Verena ;

Gebhardt, Christoffer ;

Brechtel, Ingrid ;

Duda, Angelika ;

Czerwinski, Claudia ;

Sucker, Antje ;

Holland-Letz, Tim ;

Utika, Jochen ;

Schadendorf, Dirk ;

Neumaier, Michael .

CLINICAL CHEMISTRY, 2018, 64 (05) :830-842

[3]

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.[J].Leslie Calapre;Lydia Warburton;Michael Millward;Mel Ziman;Elin S. Gray.Cancer Letters.2017,

[4] Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA [J].

Scherer, Florian ;

Kurtz, David M. ;

Newman, Aaron M. ;

Stehr, Henning ;

Craig, Alexander F. M. ;

Esfahani, Mohammad Shahrokh ;

Lovejoy, Alexander F. ;

Chabon, Jacob J. ;

Klass, Daniel M. ;

Liu, Chih Long ;

Zhou, Li ;

Glover, Cynthia ;

Visser, Brendan C. ;

Poultsides, George A. ;

Advani, Ranjana H. ;

Maeda, Lauren S. ;

Gupta, Neel K. ;

Levy, Ronald ;

Ohgami, Robert S. ;

Kunder, Christian A. ;

Diehn, Maximilian ;

Alizadeh, Ash A. .

SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (364)

[5] Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma [J].

Schreuer, Max ;

Meersseman, Geert ;

van Den Herrewegen, Sari ;

Jansen, Yanina ;

Seremet, Teofila ;

Bott, Ambre ;

Chevolet, Ines ;

Wilgenhof, Sofie ;

Maertens, Geert ;

Neyns, Bart .

MELANOMA RESEARCH, 2016, 26 (02) :157-163

[6] Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients [J].

Sakaizawa, Kaori ;

Ashida, Atsuko ;

Uchiyama, Aya ;

Ito, Takamichi ;

Fujisawa, Yasuhiro ;

Ogata, Dai ;

Matsushita, Shigeto ;

Fujii, Kazuyasu ;

Fukushima, Satoshi ;

Shibayama, Yoshitsugu ;

Hatta, Naohito ;

Takenouchi, Tatsuya ;

Uehara, Jiro ;

Okuyama, Ryuhei ;

Yamazaki, Naoya ;

Uhara, Hisashi .

JOURNAL OF DERMATOLOGICAL SCIENCE, 2015, 80 (01) :33-37

[7] Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression [J].

Chang, Gregory A. ;

Taclepalli, Jyothirmayee S. ;

Shao, Yongzhao ;

Zhang, Yilong ;

Weiss, Sarah ;

Robinson, Eric ;

Spittle, Cindy ;

Furtado, Manohar ;

Shelton, Dawne N. ;

Karlin-Neumann, George ;

Pavlick, Anna ;

Osman, Iman ;

Polsky, David .

MOLECULAR ONCOLOGY, 2016, 10 (01) :157-165

[8]

Quantitative Cell-Free Circulating BRAF^sup V600E^ Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors.[J].Sanmamed; Miguel F;Fernández-Landázuri; Sara;Rodríguez; Carmen;Zárate; Ruth;Lozano; María D;Zubiri; Leyre;Perez-Gracia; José Luis;Martín-Algarra; Salvador;González; Alvaro.Clinical Chemistry.2015, 1

← 1 →